Dual action of imeglimin on insulin secretion and sensitivity in type 2 diabetes
Main finding · Change in glucose AUC0-3h during OGTTResult — go to the resultMedian change from baseline −108.63 mg·h/dLAuthors' conclusion
These results provide the first comprehensive evidence in humans that imeglimin improves insulin secretion and insulin sensitivity in multiple tissues.
Study context
- Population
- Japanese men with T2Dclamp in 16
- Participants
- 22 men
- Comparison
- Imeglimin 2000 mg/day for 20 weeks, before vs after
- Imegliminn = 22
- Outcome
- Change from baseline in glucose AUC0-3h during the OGTT
- Follow-up
- 20 weeks
Methodological detailsdouble tracers, two-step hyperinsulinemic-euglycemic clamp
- Double tracers
- Two-step hyperinsulinemic-euglycemic clamp
Main finding
Change in glucose AUC0-3h during OGTT
Median change from baseline
−108.63 mg·h/dL
P = 0.0002
Change by group
Imeglimin
−108.63
median change · IQR −148.25–-40.75 · mg·h/dL
As reported in the abstract
Further findings
Glucose AUC0-3h during oral glucose tolerance test (OGTT) · 1 week
- A similar reduction was already evident at 1 week
- Reductions mainly attributable to a decreased rate of oral glucose appearance
Insulin secretion indices · 1 and 20 weeks
- Insulin secretion indices increased
Clamp: tissue-specific insulin sensitivity and insulin clearance · 20 weeks
- Improved insulin sensitivity in skeletal muscle, liver and adipose tissue, and increased insulin clearance
- 16 participants
Original publication
Dual action of imeglimin on insulin secretion and sensitivity in type 2 diabetes. Diabetes Obes Metab. Published 5 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →